Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement

Insight Molecular Diagnostics Inc. entered Amendment No. 2 to its merger agreement on Sept. 15, 2026. Chronix Equity Holders will receive a 10% royalty for sales of the CNI monitor.